Evotec Archives

News and Trends 24 Mar 2023

Evotec receives $6.6M for tuberculosis drug discovery

On World Tuberculosis Day, Evotec SE has announced that it has received a $ 6.6 million grant from The Bill & Melinda Gates Foundation for drug discovery to tackle tuberculosis. The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the company to progress a portfolio of TB […]

March 24, 2023 - 2 minutesmins - By Jim Cornall

Startup Scout 2 Nov 2022

Breakpoint Therapeutics sabotages DNA repair in cancer cells

The Hamburg-based Evotec spinout Breakpoint Therapeutics is working on cancer treatments that block the ability of tumor cells to repair their own DNA. In the last decade, a new class of drugs known as DNA damage response (DDR) inhibitors has risen to prominence in the oncology space. These drugs are able to break down the […]

November 2, 2022 - 4 minutesmins - By Jonathan Smith

lupus autoimmune disease neutrophil citryll

News and Trends 26 Oct 2022

Partnership for better understanding of Sjögren’s syndrome announced by Evotec

A molecular patient database for Sjögren’s syndrome (SjS) and systemic lupus erythematosus (SLE) is to be generated following a partnership between Evotec SE and a German university. Evotec made the announcement yesterday (Tuesday) that it will work with Hannover Medical School (MHH). The strategic partnership between Evotec and MHH aims at achieving a better understanding […]

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Sep 2022

Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn

Chemical bioinformatics company, Adapsyn Bioscience Inc., and Evotec SE have entered into a strategic collaboration that will allow Evotec to have the opportunity to evaluate the small molecules developed by Adapsyn. Evotec will look at the molecules as potential therapeutic candidates in proprietary and partnered drug discovery projects. The news was announced today (September 21) […]

September 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Sep 2022

Biologics manufacturing facility launched by Evotec SE in Toulouse

Construction of a biologics manufacturing facility commenced on Friday (September 16). It is being built by Evotec at its Campus Curie in Toulouse, is the second facility of its kind, and the first in Europe. It will use Just – Evotec Biologics’ flexible J.POD technology to deliver clinical and commercial manufacturing capacity for biologics. Therapeutic […]

September 19, 2022 - 2 minutesmins - By Liza Laws

News and Trends 25 Aug 2022

Evotec SE acquires highly-flexible drug manufacturing space for €1

A clinical and commercial manufacturing platform for small molecule therapeutics has expanded following an acquisition signed for. Evotec SE made the announcement today (August 25) after signing the contract yesterday for €1 to take Central Glass Germany GmbH from Japanese manufacturing company Central Glass Co. Ltd. It will now operate as Evotec Drug Substance (Germany) […]

August 25, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

Evotec completes acquisition of Rigenerand

An Italian-based cell therapy business has just been bought by Evotec SE, a German therapeutics company. Evotec just announced the strategic transaction to buy Rigenerand Srl, with the deal, signed in May 2022, now completed. Based out of Medolla, Italy, the cell technology company working in the field of cGMP manufacturing of cell therapies will […]

July 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 May 2022

Evotec adds cell therapy manufacturing facility through Rigenerand takeover

German headquartered life science company Evotec SE has acquired 100% of the capital of Rigenerand Srl, an Italian cell technology company, for €23M ($24.7M). Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia in Italy, Rigenerand is based in Medolla, Italy, about 100 km south of Evotec’s Campus Levi-Montalcini in […]

May 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 May 2022

Evotec, Sernova in partnership to develop beta cell diabetes therapy

Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in Sernova. Germany-based Evotec and Canada’s Sernova have agreed on a partnership to develop and commercialize an implantable diabetes therapy based on beta cell […]

May 19, 2022 - 3 minutesmins - By Susannah Rodgers

Best in Biotech 20 Dec 2021

The Billion-Euro European Biotech Companies in 2022

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]

December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 10 Nov 2021

Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks

German life sciences heavyweight Evotec raised around €376M ($435M) in its US debut on the Nasdaq last week, fueling tentative hopes of renewed investor interest in biotech stocks after a rollercoaster year. The company downsized its initial IPO target of around €500M ($576M) by offering fewer shares than initially planned. This is widely seen as […]

November 10, 2021 - 4 minutesmins - By Victor Kotsev

diabetes chronic kidney disease farxiga astraZeneca

News and Trends 8 Jun 2021

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

June 8, 2021 - 5 minutesmins - By Jonathan Smith

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us